Strongyloides Stercoralis Infection
10
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
10.0%
1 terminated out of 10 trials
85.7%
-0.8% vs benchmark
20%
2 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Strongyloides Stercoralis Public Health Control in Rwanda
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis
Preliminary Evaluation of Two Rapid Diagnostic Test Prototypes for Strongyloides Stercoralis Infection
The SsRI/NIE Recombinant Antigen ELISA for the Follow up of Patients Infected by Strongyloides Stercoralis
Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Treatment of Strongyloides Infection
Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
Management of Soil-transmitted Helminthiasis and Strongyloidiasis